Kizoo Technology Capital

Kizoo Technology Capital, founded in 1999 and based in Karlsruhe, Germany, specializes in mentoring and financing seed and early-stage companies with a particular emphasis on rejuvenation biotechnology. Drawing on their extensive experience as entrepreneurs and venture capitalists, Kizoo focuses on transforming research related to the root causes of aging into practical therapies and services. As part of the Forever Healthy Group, Kizoo actively supports the development of startups within this emerging sector, which is positioned to grow significantly in the future. The firm also engages in various initiatives aimed at advancing rejuvenation therapies, curating cutting-edge medical knowledge, funding relevant research projects, and organizing events like the annual Undoing Aging Conference.

Matthias Hornberger

CFO

Frank Schueler

Managing Director

45 past transactions

Cellvie

Seed Round in 2023
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying the energy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells. Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN). Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria.

Elastrin Therapeutics

Venture Round in 2022
Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work. The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

Revel Pharmaceuticals

Seed Round in 2022
Revel develops therapeutics for multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes. It is commercializing therapeutic enzymes to degrade age-associated molecule damage.

Underdog Pharmaceuticals

Seed Round in 2021
Underdog Pharmaceuticals is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration. Its products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease created through a SENS Research Foundation program.

Staffbase

Series D in 2021
Staffbase Communications Cloud provides companies with a complete platform to develop, deliver, and measure communications that inspire. The mobile compatibility of the company’s platform allows employers in manufacturing, healthcare, logistics, automotive, retail, and energy & utilities, to securely reach their employees everywhere with reduced complexity. Staffbase solutions give employees greater access to the corporate information that’s relevant to them, along with tools for the modern digital workplace, including existing intranets. Staffbase provides branded solutions for more than 2,500 leading companies worldwide who are transforming their employee communications.

Elastrin Therapeutics

Seed Round in 2021
Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work. The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

Cellvie

Seed Round in 2021
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying the energy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells. Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN). Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria.

Elevian

Venture Round in 2020
Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues. Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease.

Staffbase

Series C in 2020
Staffbase Communications Cloud provides companies with a complete platform to develop, deliver, and measure communications that inspire. The mobile compatibility of the company’s platform allows employers in manufacturing, healthcare, logistics, automotive, retail, and energy & utilities, to securely reach their employees everywhere with reduced complexity. Staffbase solutions give employees greater access to the corporate information that’s relevant to them, along with tools for the modern digital workplace, including existing intranets. Staffbase provides branded solutions for more than 2,500 leading companies worldwide who are transforming their employee communications.

Underdog Pharmaceuticals

Seed Round in 2019
Underdog Pharmaceuticals is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration. Its products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease created through a SENS Research Foundation program.

LIfT BioSciences

Series A in 2019
LIfT Biosciences® has a breakthrough allogeneic innate immuno-cell therapy platform called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) that allows us to produce different types of Immunomodulatory Alpha Neutrophils (IMAN®s) at scale from iPSCs for a wide range of different purposes as a mono or combo. LIfT BioSciences was founded in 2016 and headquartered in London, England.

Staffbase

Series C in 2019
Staffbase Communications Cloud provides companies with a complete platform to develop, deliver, and measure communications that inspire. The mobile compatibility of the company’s platform allows employers in manufacturing, healthcare, logistics, automotive, retail, and energy & utilities, to securely reach their employees everywhere with reduced complexity. Staffbase solutions give employees greater access to the corporate information that’s relevant to them, along with tools for the modern digital workplace, including existing intranets. Staffbase provides branded solutions for more than 2,500 leading companies worldwide who are transforming their employee communications.

Turn.bio

Seed Round in 2019
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platform specifically designed to enable nucleic acid therapeutics, combats the effects of aging in the epigenome, thus restoring optimal gene expression. It focuses on developing tailored therapies targeting indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

MOQO

Seed Round in 2018
MOQO is the cloud-based platform enabling everyone to offer shared mobility services with outstanding quality and exceptional economy of scale.

FoxBio

Venture Round in 2018
FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.

Staffbase

Series B in 2018
Staffbase Communications Cloud provides companies with a complete platform to develop, deliver, and measure communications that inspire. The mobile compatibility of the company’s platform allows employers in manufacturing, healthcare, logistics, automotive, retail, and energy & utilities, to securely reach their employees everywhere with reduced complexity. Staffbase solutions give employees greater access to the corporate information that’s relevant to them, along with tools for the modern digital workplace, including existing intranets. Staffbase provides branded solutions for more than 2,500 leading companies worldwide who are transforming their employee communications.

Elevian

Convertible Note in 2017
Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues. Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease.

shyftplan

Series A in 2017
shyftplan is a SaaS solution for employee management and communication. While the core product is scheduling, shyftplan brings everything together by offering solutions for absence management, time tracking, working time accounts, HR management, and payroll. HR managers are able to set up and manage shift plans and to appoint individual employees to certain shifts according to their specific competencies. shyftplan moves beyond pure workforce management functionalities by providing employee intelligence and connecting non-desk workers to their direct work environments (e.g. human-machine communication) and to their organization.

Antoxerene

Seed Round in 2017
This is a pharmaceutical company that uses proprietary next generation screening technology to identify small molecule drugs for pathways of aging. It is an affiliate of Ichor Therapeutics. Antoxerene is eager to engage collaborators in industry and academia who share its vision of delivering next generation therapies for the illnesses of aging.

AgeX Therapeutics

Venture Round in 2017
AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.

CellAge

Seed Round in 2017
We dream of a world where all people can enjoy their 80s as much as they enjoyed their 20s. A world where people no longer suffer from age-related diseases. A world where we are all given more time to spend with our loved ones.

Lysoclear

Seed Round in 2017
Lysoclear, Inc. is a pre-clinical Ichor Therapeutics portfolio company that develops enzyme therapies for eye disease. The company is currently developing leads to treat atrophic “dry” age-related macular degeneration and Stargardt’s macular degeneration.

MOQO

Seed Round in 2017
MOQO is the cloud-based platform enabling everyone to offer shared mobility services with outstanding quality and exceptional economy of scale.

Staffbase

Series A in 2016
Staffbase Communications Cloud provides companies with a complete platform to develop, deliver, and measure communications that inspire. The mobile compatibility of the company’s platform allows employers in manufacturing, healthcare, logistics, automotive, retail, and energy & utilities, to securely reach their employees everywhere with reduced complexity. Staffbase solutions give employees greater access to the corporate information that’s relevant to them, along with tools for the modern digital workplace, including existing intranets. Staffbase provides branded solutions for more than 2,500 leading companies worldwide who are transforming their employee communications.

Ichor Therapeutics

Seed Round in 2016
Ichor Therapeutics, Inc. is a pre-clinical biotechnology company located in Syracuse, NY. The company has several intramural research programs that broadly focus on therapeutic interventions for age-related disease. Ichor is also involved in several smaller ventures aimed at reducing the barriers to entry for biotechnology entrepreneurs and independent scientists.

Suitepad

Series A in 2016
2012, the idea for SuitePad was born. Merge guests' wallet, phone, remote, room-service menu, spa catalog, and newspapers on a device's vision was that for the first time was financed thanks to favorable expectant Android tablets. Product development was accompanied by renowned private and chain hoteliers from Germany, Austria, and Switzerland. So the SuitePad was very close to the actual needs of the developed chain and private hotels. After 2013, the first SuitePad installation is completed, the product is found not only in sales so far in 11 European countries, but was also honored with numerous industry-related awards. These include the u. A. CeBit BITKOM Innovation Award 2013, the Gastro Vision Award 2014 of the Travel Industry Club Best Practice Award 2014, and the HSMAI Technology and Innovation Award.

Mambu

Series B in 2016
Heard of composable banking? The concept originated here at Mambu. We’ve been champions of composable for over a decade. Mambu is the only true SaaS cloud core banking platform. Our unique and sustainable composable approach means that independent engines, systems and connectors can be assembled in any configuration to meet business requirements and the ever-changing demands of your customers. 200+ banks, lenders, fintechs, and even retailers in 60 countries turn to us to help them build modern digital financial products faster, securely and cost-effectively.

Staffbase

Seed Round in 2015
Staffbase Communications Cloud provides companies with a complete platform to develop, deliver, and measure communications that inspire. The mobile compatibility of the company’s platform allows employers in manufacturing, healthcare, logistics, automotive, retail, and energy & utilities, to securely reach their employees everywhere with reduced complexity. Staffbase solutions give employees greater access to the corporate information that’s relevant to them, along with tools for the modern digital workplace, including existing intranets. Staffbase provides branded solutions for more than 2,500 leading companies worldwide who are transforming their employee communications.

Prescreen

Seed Round in 2015
Prescreen is a cloud-based applicant tracking system that enables you to publish job vacancies online and offline and give candidates the opportunity to apply for jobs directly. Prescreen gathers all applications collectively, analyses the data and helps you with your evaluation. This makes time and labour-intensive processes more efficient.

Oisin Biotechnologies

Seed Round in 2015
Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age-related diseases. It is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces the negative effects of aging pathologies and also extends the median lifespan and survival. Oisin Biotechnologies was founded in 2014 and is headquartered in Seattle, Washington.

shyftplan

Seed Round in 2014
shyftplan is a SaaS solution for employee management and communication. While the core product is scheduling, shyftplan brings everything together by offering solutions for absence management, time tracking, working time accounts, HR management, and payroll. HR managers are able to set up and manage shift plans and to appoint individual employees to certain shifts according to their specific competencies. shyftplan moves beyond pure workforce management functionalities by providing employee intelligence and connecting non-desk workers to their direct work environments (e.g. human-machine communication) and to their organization.

Mambu

Series A in 2014
Heard of composable banking? The concept originated here at Mambu. We’ve been champions of composable for over a decade. Mambu is the only true SaaS cloud core banking platform. Our unique and sustainable composable approach means that independent engines, systems and connectors can be assembled in any configuration to meet business requirements and the ever-changing demands of your customers. 200+ banks, lenders, fintechs, and even retailers in 60 countries turn to us to help them build modern digital financial products faster, securely and cost-effectively.

Suitepad

Seed Round in 2014
2012, the idea for SuitePad was born. Merge guests' wallet, phone, remote, room-service menu, spa catalog, and newspapers on a device's vision was that for the first time was financed thanks to favorable expectant Android tablets. Product development was accompanied by renowned private and chain hoteliers from Germany, Austria, and Switzerland. So the SuitePad was very close to the actual needs of the developed chain and private hotels. After 2013, the first SuitePad installation is completed, the product is found not only in sales so far in 11 European countries, but was also honored with numerous industry-related awards. These include the u. A. CeBit BITKOM Innovation Award 2013, the Gastro Vision Award 2014 of the Travel Industry Club Best Practice Award 2014, and the HSMAI Technology and Innovation Award.

Babbel

Series B in 2013
Babbel operates an ecosystem of interconnected online language learning experiences and is driven by the purpose of creating mutual understanding through language. This means building products that help people connect and communicate across cultures. The Babbel App, Babbel Live, Podcasts and Babbel for Business products focus on using a new language in the real world, in real situations, with real people. Learners can explore the award-winning courses in the app at their own pace and take live online language classes with expert teachers. And it works: Studies by linguists from institutions such as Michigan State University, Yale University and the City University of New York demonstrated the efficacy of Babbel’s language learning methods. The key is a blend of humanity and technology. Babbel offers more than 60,000 lessons across 14 languages, hand-crafted by nearly 200 linguists and language experts, with user behaviours continuously analysed to shape and tweak the learner experience. This results in constantly adapting, interactive content with live classes, games, podcasts and videos that make understanding a new language easy, from Spanish to Indonesian. The Babbel team is as diverse as its content. From its headquarters in Berlin and its U.S. office in New York, 1000 people from more than 80 nationalities represent the backgrounds, characteristics and perspectives that make all humans unique. Babbel sold over 16 million subscriptions by creating a true connection with users. More information: www.babbel.com

Mambu

Series A in 2012
Heard of composable banking? The concept originated here at Mambu. We’ve been champions of composable for over a decade. Mambu is the only true SaaS cloud core banking platform. Our unique and sustainable composable approach means that independent engines, systems and connectors can be assembled in any configuration to meet business requirements and the ever-changing demands of your customers. 200+ banks, lenders, fintechs, and even retailers in 60 countries turn to us to help them build modern digital financial products faster, securely and cost-effectively.

Hipaway

Seed Round in 2012
Hipaway is operates as an online portal for booking hotels in Germany.

Hojoki

Series A in 2012
Hojoki makes all your cloud apps work as one. It sends push notifications and lets you discuss your work as it happens. Works with Google Docs & Drive, Google Calendar, Dropbox, Evernote, Box, Highrise, CloudApp, Delicious, Google Reader, Google Contacts, Basecamp, Twitter, Zendesk, Mendeley, Pivotal Tracker, GitHub, Ta-Da List, Salesforce Chatter, Yammer and Beanstalk.

Hojoki

Seed Round in 2011
Hojoki makes all your cloud apps work as one. It sends push notifications and lets you discuss your work as it happens. Works with Google Docs & Drive, Google Calendar, Dropbox, Evernote, Box, Highrise, CloudApp, Delicious, Google Reader, Google Contacts, Basecamp, Twitter, Zendesk, Mendeley, Pivotal Tracker, GitHub, Ta-Da List, Salesforce Chatter, Yammer and Beanstalk.

tamyca

Series A in 2011
Today tamyca GmbH develops and operates mobility platforms for OEMs, car dealers, corporates and p2p users. Tamyca - take my car launched the first and leading peer-to-peer carsharing marketplace in Germany in November 2010. Car owners whose cars would be sitting idle otherwise set up their car on tamyca, set price and availability and are ready to make some extra cash. People who need a car find those via Smartphone App or web service directly in their neighborhood, saving up to 60% compared to traditional carsharing and car rental services. Further solutions are build on On-Board Systems (in car), booking and operational software and first class customer support. Examples are: www.tamyca.de www.carunity.com www.fleetbutler.com

Pactas

Seed Round in 2011
Pactas provides a SaaS platform for recurring billing and subscription management for SaaS and subscription companies, no matter you are a startup or a well established business. Follow us: @pactashq on Twitter | pactas on Facebook

Advertory

Seed Round in 2011
Advertory was founded in 2010 in Berlin by a German-French team. The objective was to develop a platform which helps small businesses become competitive on the Internet. Advertory focuses on attracting and retaining customers for small businesses. These can find new customers easily and turn them into loyal buyers. A website with advertory is an investment which pays off quickly. Performance and success are easy to monitor. Small businesses often can not spend much time for managing websites which is why advertory runs automatically wherever possible.

MegaZebra

Series B in 2011
MegaZebra is a European Social Games developer and publisher. MegaZebra's social games and applications have been integrated into Facebook. Behind MegaZebra is a seasoned team including Henning Kosmack , Steffen Rusitschka, Christian Meister, and Mark Gazecki. In September 2009, MegaZebra received a first round financing from KIZOO Technology Ventures.

Mambu

Seed Round in 2011
Heard of composable banking? The concept originated here at Mambu. We’ve been champions of composable for over a decade. Mambu is the only true SaaS cloud core banking platform. Our unique and sustainable composable approach means that independent engines, systems and connectors can be assembled in any configuration to meet business requirements and the ever-changing demands of your customers. 200+ banks, lenders, fintechs, and even retailers in 60 countries turn to us to help them build modern digital financial products faster, securely and cost-effectively.

MegaZebra

Series A in 2010
MegaZebra is a European Social Games developer and publisher. MegaZebra's social games and applications have been integrated into Facebook. Behind MegaZebra is a seasoned team including Henning Kosmack , Steffen Rusitschka, Christian Meister, and Mark Gazecki. In September 2009, MegaZebra received a first round financing from KIZOO Technology Ventures.

Babbel

Seed Round in 2008
Babbel operates an ecosystem of interconnected online language learning experiences and is driven by the purpose of creating mutual understanding through language. This means building products that help people connect and communicate across cultures. The Babbel App, Babbel Live, Podcasts and Babbel for Business products focus on using a new language in the real world, in real situations, with real people. Learners can explore the award-winning courses in the app at their own pace and take live online language classes with expert teachers. And it works: Studies by linguists from institutions such as Michigan State University, Yale University and the City University of New York demonstrated the efficacy of Babbel’s language learning methods. The key is a blend of humanity and technology. Babbel offers more than 60,000 lessons across 14 languages, hand-crafted by nearly 200 linguists and language experts, with user behaviours continuously analysed to shape and tweak the learner experience. This results in constantly adapting, interactive content with live classes, games, podcasts and videos that make understanding a new language easy, from Spanish to Indonesian. The Babbel team is as diverse as its content. From its headquarters in Berlin and its U.S. office in New York, 1000 people from more than 80 nationalities represent the backgrounds, characteristics and perspectives that make all humans unique. Babbel sold over 16 million subscriptions by creating a true connection with users. More information: www.babbel.com
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.